Klygefa (gefurulimab) approved in the EU

Summary by AI BETAClose X

AstraZeneca's Alexion unit received European Commission approval for Klygefa (gefurulimab) as an add‑on for AChR‑positive gMG, based on the 260‑patient PREVAIL Phase III trial showing a treatment difference in MG‑ADL of −1.6 (95% CI −2.4 to −0.8; p<0.0001) with clinically meaningful improvement from week 1 sustained to week 26; Klygefa is the first‑and‑only dual‑binding nanobody C5 inhibitor in the EU, offers once‑weekly subcutaneous autoinjector dosing, targets an estimated 82,500 diagnosed gMG patients in five major EU countries of whom ~66,000 are AChR‑positive, and is already approved in the US and Japan.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings